Canine splenic hemangiosarcoma cells express and activate luteinizing hormone receptors in vitro.
Journal
American journal of veterinary research
ISSN: 1943-5681
Titre abrégé: Am J Vet Res
Pays: United States
ID NLM: 0375011
Informations de publication
Date de publication:
07 Nov 2022
07 Nov 2022
Historique:
pubmed:
4
11
2022
medline:
6
12
2022
entrez:
3
11
2022
Statut:
epublish
Résumé
To determine luteinizing hormone receptor (LHR) expression and response to LHR activation in isolated canine splenic hemangiosarcoma cell lines in vitro. In vitro cultures of commercially available canine splenic hemangiosarcoma cell lines (EFS, GRACE-HSA, and DAL-4). The percentage of each cell line expressing LHR was determined by immunocytochemistry. Cells were then treated with increasing doses (7.5 ng/mL, 75 ng/mL) of recombinant canine luteinizing hormone (cLH) for 48 hours and evaluated using a cell proliferation assay. The percentage of cells expressing LHR was 17.2 ± 4.5%, 11.8 ± 3.1%, and 6.9 ± 2.5% in EFS, GRACE-HSA, and DAL-4, respectively. There was significant increase in cell count in the DAL-4 and EFS cell lines following a 48-hour incubation at the highest cLH concentration (P = .028 and P = .019, respectively). There was not a significant increase in cell count in the GRACE-HSA cell line at either cLH concentration. Activation of LHR results in cell proliferation in some canine splenic hemangiosarcoma cell lines. These results may explain why spayed and castrated dogs with high circulating LH concentrations may develop hemangiosarcoma more frequently than intact dogs.
Identifiants
pubmed: 36327166
pii: ajvr.22.07.0120
doi: 10.2460/ajvr.22.07.0120
doi:
pii:
Substances chimiques
Receptors, LH
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM